Table 5.

Relationship between GPR126 mutation status and standard clinical, pathologic, and biological parameters in MIBC

GPR126 mutatedGPR126 not mutated
Total population (%)N (%)N (%)Pa
Total population59 (100.0)26 (44.1)33 (55.9)
Age (years)
 ≥6043 (72.9)19 (44.2)24 (55.8)0.98
 <6016 (27.1)7 (43.8)9 (56.3)
Sex
 Male45 (76.3)15 (33.3)30 (66.7)0.0029
 Female14 (23.7)11 (78.6)3 (21.4)
Smoking statusb
 Nonsmoker9 (17.0)4 (44.4)5 (55.6)0.85
 Smoker44 (83.0)21 (47.7)23 (52.3)
History of NMIBC
 No35 (59.3)13 (37.1)22 (62.9)0.20
 Yes24 (40.7)13 (54.2)11 (45.8)
Associated pTis
 No52 (88.1)22 (42.3)30 (57.7)0.74
 Yes7 (11.9)4 (57.1)3 (42.9)
Tumor stage
 T221 (35.6)9 (42.9)12 (57.1)0.89
 ≥T338 (64.4)17 (44.7)21 (55.3)
Lymph node statusc
 N−37 (64.9)16 (43.2)21 (56.8)0.81
 N+20 (35.1)8 (40.0)12 (60.0)
FGFR3 status
 Mutated6 (10.2)3 (50.0)3 (50.0)>0.99
 Not mutated53 (89.9)23 (43.4)30 (56.6)
PIK3CA status
 Mutated6 (10.2)3 (50.0)3 (50.0)>0.99
 Not mutated53 (89.9)23 (43.4)30 (56.6)
  • NOTE: P < 0.05 are in bold.

  • aχ2 test, χ2 test with Yates' correction, or Fisher test if appropriate.

  • bData available for 53 patients.

  • cData available for 57 patients.